Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

Pulse Biosciences reported third-quarter 2026 results for the period ended September 30, but the article did not provide revenue, profit, or other financial figures. The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of plan, as it advances clinical and commercial programs using its Nanosecond Pulsed Field Ablation technology. The article did not report a stock-price movement.